TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| FDA Requires Faster Food-Safety Alerts The FDA launched its electronic food registry for companies to quickly report potential food-borne illnesses to the federal government. online.barrons.com |
FDA Narrowly Clears Melanoma Drug An FDA panel narrowly backed the use of Schering Plough's Pegintron in patients with advanced melanoma amid concerns about drug side-effects. online.barrons.com |
Drug Makers Face Tougher Measures The House health-care bill presents more problems for drug makers than legislation in the Senate, but it gives the medical-device industry better breaks. online.wsj.com |
Ziopharm: The Money's in the Bank, So What's Next? Wall Street Teacher submits:On Friday, December 4th, Ziopharm Oncology Inc. (ZIOP) announced a public offering of 15.5 million common shares and warrants to buy 7.7 million shares in a public offering. The deal was priced @ $3.10 per unit and netted the company approximately $45.2 million. For a micro cap, this was a large, fairly dilutive deal. Common shares now stand at 41,192,287 with a market cap of roughly $125 million.First, the negatives--dilution, dilution, dilution. Rodman & Renshaw, LLC,was involved in the transaction. Experience tells me that they are not the most discriminating firm when it comes to stock placement. Many R & R clients are rumored to have no interest in holding positions long term, but merely flip the shares and strip the warrants in unit deals. This may explain the weak aftermarket performance of the stock. (Currently trading @ $ 3.02) Also, since the warrants are exercisable @ $4.02, there may be a short term cap on the share price. Why the big raise? With $7 million in the bank (pre-raise), I believe that Ziopharm was likely low-balled in any partnering discussions so the public offering may (in the long term) turn out to be the wise decision.Complete Story » seekingalpha.com |
Are Forest Labs' Fans Right? Forest Labs (FRX) is among the stock picks in this weekend's Barron's. Staff writer Jay Palmer does an excellent job laying out the bull case for FRX shares in Forest Lab's Prescription for Success. An unappreciated pipeline plus a huge cash horde add up to a winning combination. He isn't the first to think so.Forest Labs has been a Lonely Value favorite for exactly these reasons. My first Forest post (See the Forest for its Cash) appeared in June of 2009. At the time, the company had $3 billion in cash and securities (zero debt) against a $7.4 billion market value. Fully 40% of Forest's market value was in cash and marketable securities. In addition, FRX was churning out over $1 billion a year in free cash flow. It still does.Complete Story » seekingalpha.com |